ファーマコゲノミクス市場：製品別、技術別、用途別、エンドユーザー別 - 世界予測（2031年まで）

ファーマコゲノミクス市場は、2024年から2031年までのCAGRが8.9%で、2030年までには195億米ドルに達すると予測されています。

本レポートでは、広範な1次調査と2次調査、市場シナリオの詳細な分析により、主要な業界促進要因、抑制要因、課題、機会を調査しています。ファーマコゲノミクス市場の成長の背景には、ファーマコゲノミクスバイオマーカーの治療用途の拡大、個別化医薬品の採用拡大、高齢者人口の増加と慢性疾患の流行、米国FDAとEMAによる創薬・開発におけるファーマコゲノミクスデータの使用推奨などがあります。しかし、個別化医薬品のコストが高いことがこの市場の成長を抑制しています。

さらに、神経疾患やがんの治療におけるファーマコゲノミクスの応用の拡大、精度を向上させた新しいより高度な診断ツールの開拓、薬物有害反応に関する意識の高まりは、ファーマコゲノミクス市場で活動するプレーヤーに成長機会をもたらすと期待されています。しかし、ファーマコゲノミクスと個別化医療に対する認知度の低さ、遺伝子検査とその利点に対する理解の浅さ、遺伝子検査と精密医療に対する償還の不足は、市場成長に影響を与える大きな課題です。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場洞察

• 概要
• 市場成長に影響を与える要因
  • 市場力学
  • 要因分析
• 主要動向
  • シーケンシングのコスト低下により、ファーマコゲノミクス検査がより手頃な価格に
  • ファーマコゲノミクスにおけるAIの可能性の高まり
• 規制分析
  • 米国
  • カナダ
  • 欧州
  • 中国
  • 日本
  • インド
  • ラテンアメリカ
  • 中東・アフリカ
• 価格分析
• ポーターのファイブフォース分析

第5章 ファーマコゲノミクス市場評価：製品別

• 概要
• 消耗品
• 機器
• ソフトウェアとサービス

第6章 ファーマコゲノミクス市場評価： 技術別

• 概要
• ポリメラーゼ連鎖反応（PCR）
• シーケンシング
• マイクロアレイ
• 質量分析
• 電気泳動
• その他の技術

第7章 世界のファーマコゲノミクス市場評価：用途別

• 概要
• がん領域
• メンタルヘルス
• 感染症
• 循環器
• 神経疾患
• その他の用途

第8章 ファーマコゲノミクス市場評価：エンドユーザー別

• 概要
• 病院・診断研究所
• 学術・研究機関
• その他のエンドユーザー

第9章 ファーマコゲノミクス市場評価：地域別

• 概観
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第10章 競合分析

• 概要
• 主要成長戦略
• 競合ベンチマーキング
• 競合ダッシュボード
  • 業界リーダー
  • 市場差別化要因
  • 先行企業
  • 新興企業
• 市場ランキング（2023年）
  • Thermo Fisher Scientific, Inc. （米国）
  • Illumina, Inc.（米国）
  • Danaher Corporation（米国）
  • F. Hoffmann-La Roche Ltd.（スイス）

第11章 企業プロファイル（事業概要、財務スナップショット、製品ポートフォリオ、戦略的展開、SWOT分析）

• F. Hoffmann La-Roche Ag
• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Danaher Corporation
• Agilent Technologies, Inc.
• Qiagen N.V.
• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• PerkinElmer, Inc.
• Pacific Biosciences of California, Inc.

（注：上位5社のSWOT分析を掲載予定）

第12章 付録

• Table 1 Pharmacogenomics Instruments: Pricing
• Table 2 Global Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 3 Global Pharmacogenomic Consumables Market, by Country/Region, 2022-2031 (USD Million)
• Table 4 Global Pharmacogenomic Instruments Market, by Country/Region, 2022-2031 (USD Million)
• Table 5 Global Pharmacogenomic Software & Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 6 Advantages and Disadvantages of Technologies for Pharmacogenomics
• Table 7 Global Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
• Table 8 Global Pharmacogenomics Market for Polymerase Chain Reaction, by Country/Region, 2022-2031 (USD Million)
• Table 9 Global Pharmacogenomics Market for Sequencing, by Country/Region, 2022-2031 (USD Million)
• Table 10 Global Pharmacogenomics Market for Microarrays, by Country/Region, 2022-2031 (USD Million)
• Table 11 Global Pharmacogenomics Market for Mass Spectrometry, by Country/Region, 2022-2031 (USD Million)
• Table 12 Global Pharmacogenomics Market for Electrophoresis, by Country/Region, 2022-2031 (USD Million)
• Table 13 Global Pharmacogenomics Market for Other Technologies, by Country/Region, 2022-2031 (USD Million)
• Table 14 Global Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
• Table 15 Number of New Cancer Cases, by Region, 2020 Vs. 2040 (In Million)
• Table 16 Global Pharmacogenomics Market for Oncology, by Country/Region, 2022-2031 (USD Million)
• Table 17 Global Pharmacogenomics Market for Mental Health, by Country/Region, 2022-2031 (USD Million)
• Table 18 HIV Statistics (2021)
• Table 19 Global Pharmacogenomics Market for Infectious Diseases, by Country/Region, 2022-2031 (USD Million)
• Table 20 Global Pharmacogenomics Market for Cardiology, by Country/Region, 2022-2031 (USD Million)
• Table 21 Global Pharmacogenomics Market for Neurological Disorders, by Country/Region, 2022-2031 (USD Million)
• Table 22 Global Pharmacogenomics Market for Other Applications, by Country/Region, 2022-2031 (USD Million)
• Table 23 Global Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
• Table 24 Global Pharmacogenomics Market for Hospitals & Diagnostic Laboratories, by Country/Region, 2022-2031 (USD Million)
• Table 25 Global Pharmacogenomics Market for Academic & Research Institutes, by Country/Region, 2022-2031 (USD Million)
• Table 26 Global Pharmacogenomics Market for Other End Users, by Country/Region, 2022-2031 (USD Million)
• Table 27 Global Pharmacogenomics Market, by Country/Region, 2022-2031 (USD Million)
• Table 28 North America: Pharmacogenomics Market, by Country, 2022-2031 (USD Million)
• Table 29 North America: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 30 North America: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
• Table 31 North America: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
• Table 32 North America: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
• Table 33 U.S.: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 34 U.S.: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
• Table 35 U.S.: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
• Table 36 U.S.: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
• Table 37 Canada: Diabetes Prevalence 2023 Vs 2033
• Table 38 Canada: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 39 Canada: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
• Table 40 Canada: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
• Table 41 Canada: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
• Table 42 Europe: Ubiquitous Pharmacogenomics Contributions (USD Million)
• Table 43 Europe: Pharmacogenomics Market, by Country/Region, 2022-2031 (USD Million)
• Table 44 Europe: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 45 Europe: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
• Table 46 Europe: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
• Table 47 Europe: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
• Table 48 Germany: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 49 Germany: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
• Table 50 Germany: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
• Table 51 Germany: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
• Table 52 France: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 53 France: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
• Table 54 France: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
• Table 55 France: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
• Table 56 U.K. Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 57 U.K. Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
• Table 58 U.K. Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
• Table 59 U.K. Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
• Table 60 Italy: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 61 Italy: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
• Table 62 Italy: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
• Table 63 Italy: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
• Table 64 Spain: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 65 Spain: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
• Table 66 Spain: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
• Table 67 Spain: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
• Table 68 Rest of Europe: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 69 Rest of Europe: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
• Table 70 Rest of Europe: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
• Table 71 Rest of Europe: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
• Table 72 Asia-Pacific: Pharmacogenomics Market, by Country/Region, 2022-2031 (USD Million)
• Table 73 Asia-Pacific: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 74 Asia-Pacific: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
• Table 75 Asia-Pacific: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
• Table 76 Asia-Pacific: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
• Table 77 China: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 78 China: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
• Table 79 China: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
• Table 80 China: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
• Table 81 Japan: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 82 Japan: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
• Table 83 Japan: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
• Table 84 Japan: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
• Table 85 India: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 86 India: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
• Table 87 India: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
• Table 88 India: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
• Table 89 Rest of Asia-Pacific: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 90 Rest of Asia-Pacific: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
• Table 91 Rest of Asia-Pacific: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
• Table 92 Rest of Asia-Pacific: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
• Table 93 Latin America: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 94 Latin America: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
• Table 95 Latin America: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
• Table 96 Latin America: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
• Table 97 Middle East & Africa: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 98 Middle East & Africa: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
• Table 99 Middle East & Africa: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
• Table 100 Middle East & Africa: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
• Table 101 Recent Developments, by Company (2020-2023)

LIST OF FIGURES

• Figure 1 Research Process
• Figure 2 Secondary Sources Referenced for This Study
• Figure 3 Primary Research Techniques
• Figure 4 Key Executives Interviewed
• Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
• Figure 6 Market Sizing and Growth Forecast Approach
• Figure 7 Global Pharmacogenomics Market, by Offerings, 2024 Vs. 2031 (USD Million)
• Figure 8 Global Pharmacogenomics Market, by Technology, 2024 Vs. 2031 (USD Million)
• Figure 9 Global Pharmacogenomics Market, by Application, 2024 Vs. 2031 (USD Million)
• Figure 10 Global Pharmacogenomics Market, by End User, 2024 Vs. 2031 (USD Million)
• Figure 11 Global Pharmacogenomics Market, by Geography
• Figure 12 Impact Analysis of Market Dynamics
• Figure 13 Percentage Share of U.S. FDA-Approved PGx-Labeled Drugs, by Application (As of June 2023)
• Figure 14 U.S.: Number of Personalized Medicines on The Market, 2008-2020
• Figure 15 Molecular and Cell-Based Therapies (As a Percentage of Total FDA-Approved Therapies), 2015-2021
• Figure 16 Global Estimated Number of New Cancer Cases, 2020-2040 (In Million)
• Figure 17 Genome Sequencing Costs, 2010-2022 (USD)
• Figure 18 USFDA Regulatory Pathways for Pharmacogenomics Products
• Figure 19 EU Regulatory Pathway - IVDR 2017/746
• Figure 20 China: Medical Device Classification and Pre-Market Requirements for IVD Devices
• Figure 21 Porter's Five Forces Analysis
• Figure 22 Global Pharmacogenomics Market, by Offering, 2024 Vs. 2031 (USD Million)
• Figure 23 Global Estimated Number of New Cancer Cases (2020-2040) (Million)
• Figure 24 Global Pharmacogenomics Market, by Technology, 2024 Vs. 2031 (USD Million)
• Figure 25 Global Pharmacogenomics Market, by Application, 2024 Vs. 2031 (USD Million)
• Figure 26 Estimated Number of New Cancer Cases, 2020 Vs. 2040
• Figure 27 Global Pharmacogenomics Market, by End User, 2023 Vs. 2030 (USD Million)
• Figure 28 Global Pharmacogenomics Market Assessment, by Country/Region, 2024-2031 (USD Million)
• Figure 29 North America: Pharmacogenomics Market Snapshot
• Figure 30 Precision Medicine Research Funding To NIH, 2018-2024 (USD Million)
• Figure 31 Europe: Pharmacogenomics Market Snapshot
• Figure 32 Germany: Estimated Number of New Cancer Cases, 2020-2035 (In Thousand)
• Figure 33 France: Total Number of People with Dementia, 2018-2050 (In Thousands)
• Figure 34 Asia-Pacific: Pharmacogenomics Market Snapshot
• Figure 35 Key Growth Strategies Adopted by Leading Market Players (2020-2023)
• Figure 36 Pharmacogenomics Market: Competitive Benchmarking, by Offering
• Figure 37 Pharmacogenomics Market: Competitive Benchmarking, by Region
• Figure 38 Competitive Dashboard: Pharmacogenomics Market
• Figure 39 Global Pharmacogenomics Market Ranking, by Key Players (2023)
• Figure 40 F. Hoffmann La-Roche Ltd.: Financial Snapshot (2022)
• Figure 41 Thermo Fisher Scientific, Inc.: Financial Overview (2022)
• Figure 42 Illumina, Inc.: Financial Overview (2022)
• Figure 43 Danaher Corporation: Financial Overview (2022)
• Figure 44 Agilent Technologies, Inc.: Financial Snapshot (2023)
• Figure 45 Qiagen N.V.: Financial Snapshot (2022)
• Figure 46 Abbott Laboratories: Financial Overview (2022)
• Figure 47 Bio-Rad Laboratories, Inc.: Financial Overview (2022)
• Figure 48 PerkinElmer, Inc.: Financial Overview (2022)
• Figure 49 Pacific Biosciences of California, Inc.: Financial Overview (2022)

The pharmacogenomics market is expected to reach $19.5 billion by 2030, at a CAGR of 8.9% from 2024 to 2031.

With extensive primary and secondary research and in-depth analysis of the market scenario, the report studies the key industry drivers, restraints, challenges, and opportunities. The growth of the pharmacogenomics market is attributed to the growing therapeutic applications of pharmacogenomic biomarkers, the increasing adoption of personalized medicines, the rising geriatric population and chronic disease prevalence, and the U.S. FDA's and EMA's recommendations for using pharmacogenomic data in drug discovery & development. However, the high costs of personalized medicines restrain the growth of this market.

Furthermore, the increasing application of pharmacogenomics in the treatment of neurological disorders and cancers, the development of new, more advanced diagnostic tools with improved accuracy, and growing awareness regarding adverse drug reactions are expected to generate growth opportunities for the players operating in the pharmacogenomics market. However, low awareness about pharmacogenomics and personalized medicine, the limited understanding of genetic testing and its benefits, and the lack of reimbursements for genetic testing and precision medicine are major challenges impacting market growth.

Based on offering, the global pharmacogenomics market is segmented into consumables, instruments, and software & services. In 2024, the consumables segment is expected to account for the largest share of the market. The largest market share of this segment is attributed to the recurrent use of consumables over instruments and the high burden of chronic diseases. Moreover, the high increasing prevalence of chronic diseases coupled with the focus of players for the launch of advanced and better reagents & kits drives the segment growth.

Based on technology, the global pharmacogenomics market is segmented into polymerase chain reaction (PCR), sequencing, microarray, mass spectrometry, electrophoresis, and other technologies. In 2024, the polymerase chain reaction (PCR) segment is expected to account for the largest share of the pharmacogenomics market. The large market share of this segment is attributed to the high sensitivity, accuracy, low sample volume requirements, and cost-effectiveness coupled with the high presence of PCR base across all the end users, initiatives by players to launch and get approvals for new PCR products for pharmacogenomics, and a wide range of applications of the PCR.

Based on application, the global pharmacogenomics market is segmented into oncology, mental health cardiology, neurological disorders, infectious diseases, and other applications. The oncology segment is expected to register the fastest CAGR during the forecast period of 2024-2031. The fast growth of this segment is attributed to the increasing prevalence of cancer cases and the need for targeted cancer treatment, growing demand for precision oncology, and growing research activities for precision oncology.

Based on end user, the global pharmacogenomics market is segmented into hospitals & diagnostic laboratories, academic and research institutes, and other end users. In 2024, the hospitals & diagnostic laboratories segment is expected to account for the largest share of the global pharmacogenomics Market. The large market share of this segment is attributed to the growing adoption of precision medicine, the growing prevalence of chronic diseases, the large number of clinical trials conducted at hospitals and diagnostic laboratories, and the focus of pharmacogenomic testing services companies on acquisitions and launches of pharmacogenomic testing services. For instance, in 2023, Incite Health Pty Limited (Australia), a pharmacogenomic testing company, acquired CNSDose LLC (U.S.), a pharmacogenomic test provider.

An in-depth analysis of the geographical scenario of the pharmacogenomics market provides detailed qualitative and quantitative insights into five major geographies: North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, along with the coverage of major countries in each region. Asia-Pacific is slated to register the highest CAGR during the forecast period. Rising government spending to increase testing capacities; increasing cases of inherited diseases such as Down Syndrome, cystic fibrosis, sickle cell disease, colon (colorectal) cancer, and breast cancer; growing awareness about the significance of genetic tests; and increasing government initiatives promoting genetic testing contribute to the growth of the market.

Some of the key players operating in the global pharmacogenomics market are F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), QIAGEN N.V. (Netherlands), and Pacific Biosciences of California, Inc. (U.S.).

Scope of the Report:

Pharmacogenomics Market, by Offering

• Instruments
• Consumables
• Software & Services

Pharmacogenomics Market, by Technology

• Polymerase Chain Reaction
• DNA Sequencing
• Electrophoresis
• Microarray
• Mass Spectrometry
• Other Technologies

(Note: Other Technologies include nucleic acid amplification technology and in situ hybridization)

Pharmacogenomics Market, by Application

• Oncology
• Mental Health
• Cardiology
• Neurological Disorders
• Infectious Diseases
• Other Applications

(Note: Other Applications include pain management, adverse drug reactions, autoimmune diseases, metabolic disorders, pulmonary diseases, hematology, dermatology, transplantation, urology, analgesia, anesthesiology, antidotal therapy, and forensic pathology)

Pharmacogenomics Market, by End User

• Hospitals & Diagnostic Laboratories
• Academic & Research Institutes
• Other End Users

(Other End Users include pharmaceutical & biotechnology companies, clinical research organizations (CROS), and forensic laboratories)

Pharmacogenomics Market, by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia-Pacific (APAC)
  • Japan
  • China
  • India
  • Rest of Asia-Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition & Scope
• 1.2. Market Ecosystem
• 1.3. Currency & Limitations
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Process Of Data Collection and Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders from The Industry
• 2.3. Market Sizing and Forecasting
  • 2.3.1. Market Size Estimation Approach
  • 2.3.2. Growth Forecast Approach
• 2.4. Assumptions For the Study

3. Executive Summary

4. Market Insights

• 4.1. Overview
• 4.2. Factors Affecting Market Growth
  • 4.2.1. Market Dynamics
    • 4.2.1.1. Growing Therapeutic Applications of Pharmacogenomic Biomarkers Supporting Market Growth
    • 4.2.1.2. Increasing Adoption of Personalized Medicines Driving the Demand for Pharmacogenomics
    • 4.2.1.3. Rising Geriatric Population and Chronic Disease Prevalence Boosting Pharmacogenomic Research and Testing
    • 4.2.1.4. The U.S. FDA's And EMA's Recommendations for Using Pharmacogenomic Data in Drug Discovery & Development Accelerating Market Expansion
    • 4.2.1.5. Growing Awareness Regarding Adverse Drug Reactions (ADRs) Generating Opportunities for Market Players
    • 4.2.1.6. Low Awareness About Pharmacogenomics and Personalized Medicine to Remain a Major Challenge for Market Stakeholders
    • 4.2.1.7. Lack Of Reimbursements for Genetic Testing and Precision Medicine Impacting Market Growth
  • 4.2.2. Factors Analysis
• 4.3. Key Trends
  • 4.3.1. Declining Costs of Sequencing Making Pharmacogenomic Testing More Affordable
  • 4.3.2. Increasing Potential of AI In Pharmacogenomics
• 4.4. Regulatory Analysis
  • 4.4.1. U.S
  • 4.4.2. Canada
  • 4.4.3. Europe
  • 4.4.4. China
  • 4.4.5. Japan
  • 4.4.6. India
  • 4.4.7. Latin America
  • 4.4.8. Middle East & Africa
• 4.5. Pricing Analysis
• 4.6. Porter's Five Forces Analysis
  • 4.6.1. Bargaining Power of Buyers
  • 4.6.2. Bargaining Power of Suppliers
  • 4.6.3. Threat Of Substitutes
  • 4.6.4. Threat Of New Entrants
  • 4.6.5. Degree Of Competition

5. Pharmacogenomics Market Assessment-by Offering

• 5.1. Overview
• 5.2. Consumables
• 5.3. Instruments
• 5.4. Software & Services

6. Pharmacogenomics Market Assessment-by Technology

• 6.1. Overview
• 6.2. Polymerase Chain Reaction (PCR)
• 6.3. Sequencing
• 6.4. Microarray
• 6.5. Mass Spectrometry
• 6.6. Electrophoresis
• 6.7. Other Technologies

7. Global Pharmacogenomics Market Assessment-by Application

• 7.1. Overview
• 7.2. Oncology
• 7.3. Mental Health
• 7.4. Infectious Diseases
• 7.5. Cardiology
• 7.6. Neurological Disorders
• 7.7. Other Applications

8. Pharmacogenomics Market Assessment-by End User

• 8.1. Overview
• 8.2. Hospitals & Diagnostic Laboratories
• 8.3. Academic & Research Institutes
• 8.4. Other End Users

9. Pharmacogenomics Market Assessment-by Geography

• 9.1. Overview
• 9.2. North America
  • 9.2.1. U.S.
  • 9.2.2. Canada
• 9.3. Europe
  • 9.3.1. Germany
  • 9.3.2. France
  • 9.3.3. U.K.
  • 9.3.4. Italy
  • 9.3.5. Spain
  • 9.3.6. Rest Of Europe
• 9.4. Asia-Pacific
  • 9.4.1. China
  • 9.4.2. Japan
  • 9.4.3. India
  • 9.4.4. Rest Of Asia-Pacific
• 9.5. Latin America
• 9.6. Middle East & Africa

10. Competition Analysis

• 10.1. Overview
• 10.2. Key Growth Strategies
• 10.3. Competitive Benchmarking
• 10.4. Competitive Dashboard
  • 10.4.1. Industry Leaders
  • 10.4.2. Market Differentiators
  • 10.4.3. Vanguards
  • 10.4.4. Emerging Companies
• 10.5. Market Ranking (2023)
  • 10.5.1. Thermo Fisher Scientific, Inc. (U.S.)
  • 10.5.2. Illumina, Inc. (U.S.)
  • 10.5.3. Danaher Corporation (U.S.)
  • 10.5.4. F. Hoffmann-La Roche Ltd. (Switzerland)

11. Company Profiles (Business Overview, Financial Snapshot, Product Portfolio, Strategic Developments, and SWOT Analysis)

• 11.1. F. Hoffmann La-Roche Ag
• 11.2. Thermo Fisher Scientific, Inc.
• 11.3. Illumina, Inc.
• 11.4. Danaher Corporation
• 11.5. Agilent Technologies, Inc.
• 11.6. Qiagen N.V.
• 11.7. Abbott Laboratories
• 11.8. Bio-Rad Laboratories, Inc.
• 11.9. PerkinElmer, Inc.
• 11.10. Pacific Biosciences of California, Inc.

(Note: SWOT Analysis of Top 5 Companies Will Be Provided)

12. Appendix

• 12.1. Available Customization
• 12.2. Related Reports